“Our data show that the infecting pathogen in bronchiolitis affects hospital length-of-stay,” says Jonathan Mansbach, MD, a hospitalist physician at Boston Children’s and first author of the study, published online April 2 by the Archives of Pediatrics & Adolescent Medicine. “Most research on treatments currently lumps all children with bronchiolitis together, and may miss findings that are important in a particular subgroup.”
Mansbach and senior investigator Carlos A. Camargo, MD, DrPH, of Massachusetts General Hospital, tracked more than 2,200 children under age 2 who were hospitalized with bronchiolitis during the 2007 to 2010 winter seasons, as part of the Multicenter Airway Research Collaboration (MARC), a program of the Emergency Medicine Network (EMNet) (www.emnet-usa.org). PCR testing was done for multiple viruses and bacteria.
While most infants in the study had respiratory syncytial virus (RSV), a quarter were infected with the common cold virus (rhinovirus). These infants were less likely than those with RSV to have hospital stays of three days or longer (odds ratio, 0.36). Compared with infants infected with RSV alone, infants with rhinovirus alone were less likely to have hospital stays of three days or longer (odds ratio, 0.36) after adjustment for other factors affecting disease severity. Infants with both RSV and rhinovirus were morelikely to have 3-day or longer stays than infants with RSV alone (odds ratio, 1.33).
“There seems to be some interaction between RSV and rhinovirus that needs further study,” Mansbach says.
The findings also call into question a common hospital practice of rooming babies with RSV bronchiolitis together. Although this practice is frequently necessary, it has the potential to expose children to new infections. In the study, at least one other virus was detected in 32 percent of the RSV-positive babies and in 23 percent of RSV-negative babies. And some of the co-infecting pathogens require different kinds of infection-control precautions in the hospital, Mansbach says.
Currently, there is much variability in how babies with bronchiolitis are treated, with nothing consistently proven to be beneficial aside from supportive measures. Under a new five-year grant, Mansbach and colleagues have begun a study to test and track children hospitalized with bronchiolitis prospectively, to see if the type of infecting virus, among many other factors, predicts long-term outcomes such as recurrent wheezing at age 3 or asthma at age 6.
The study was funded by grants U01 AI-67693, K23 AI-77801, and UL1 RR- 031988 from the National Institute of Allergy and Infectious Diseases, the National Center for Research Resources and the National Institutes of Health.
Children’s Hospital Boston
Boston Children’s Hospital is home to the world’s largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Boston Children’s research community. Founded as a 20-bed hospital for children, Boston Children’s today is a 395 bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children’s also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children’s, visit: http://vectorblog.org.